PHR:NYE-Phreesia Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 26.55

Change

+0.35 (+1.34)%

Market Cap

N/A

Volume

0.40M

Analyst Target

USD 30.11
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-06 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

+0.94 (+1.37%)

USD 10.78B
DOCS Doximity Inc

-0.09 (-0.16%)

USD 9.97B
WEAV Weave Communications Inc

-0.26 (-1.61%)

USD 1.13B
MPLN MultiPlan Corporation

-0.35 (-2.81%)

USD 0.23B
AMWL American Well Corp

-0.15 (-1.99%)

USD 0.11B
OWLT Owlet Inc

-0.10 (-2.17%)

USD 0.08B
TDOC Teladoc Inc

+0.06 (+0.60%)

N/A
FOXO FOXO Technologies Inc.

N/A

N/A
EVH Evolent Health Inc

-0.04 (-0.33%)

N/A
VEEV Veeva Systems Inc Class A

-1.14 (-0.54%)

N/A

ETFs Containing PHR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.52% 82% B 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.52% 82% B 92% A
Trailing 12 Months  
Capital Gain 13.95% 80% B- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.95% 80% B- 62% D
Trailing 5 Years  
Capital Gain -2.07% 50% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.07% 50% F 25% F
Average Annual (5 Year Horizon)  
Capital Gain 10.96% 70% C- 67% D+
Dividend Return 10.96% 70% C- 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 66.63% 60% D- 14% F
Risk Adjusted Return 16.46% 80% B- 32% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector